A Proven Team of Industry Leaders and Innovators


Founded in 2018, Sandhill Therapeutics has harnessed the power of Natural Killer (NK) cells and innate T cell populations to maximize tumor killing and to provide a cost-effective, universal, immediately available, cellular immuno-oncology therapy.

  • More than 150 combined years of experience in translation, product development, clinical development, manufacturing, and regulatory in the cell/gene therapy space
  • Product and clinical experience in both autologous and allogeneic cell/gene therapies
  • Experience with cGMP and GCP regulatory activities; participated in EMA submission for ATMP product
  • Network of cell/gene therapy resources ready to develop commercially attractive off-the-shelf cellular immuno-oncology therapeutics



Sandhill Team

Card image

Annemarie Moseley MD PhD
CEO, Director

Card image

RA Session II
Director

Card image

Henri Boodée MD MBA
VP Clinical Development & Medical Affairs

Card image

Cassandra Harrison MPH MBA
VP Clinical Operations &
Data Management

Card image

Ken Moseley
Legal, Director

Card image

Richard Turner PhD
Consultant, CMC

Card image

Natalie Thomas PhD
Consultant, Preclinical